These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11932320)

  • 21. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leptin, gastrointestinal and stress hormones in response to exercise in fasted or fed subjects and before or after blood donation.
    Sliwowski Z; Lorens K; Konturek SJ; Bielanski W; Zoładź JA
    J Physiol Pharmacol; 2001 Mar; 52(1):53-70. PubMed ID: 11321513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
    Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
    J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
    J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegvisomant in the treatment of acromegaly.
    Parkinson C; Scarlett JA; Trainer PJ
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
    Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
    Chen HS; Wu TE; Jap TS; Hsiao LC; Lin HD; Lee SH; Lin SH
    Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly.
    Jansen RW; Peeters TL; Lenders JW; van Lier HJ; v't Laar A; Hoefnagels WH
    J Clin Endocrinol Metab; 1989 Apr; 68(4):752-6. PubMed ID: 2646315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1992 Dec; 75(6):1459-63. PubMed ID: 1281485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pituitary-independent effect of octreotide on IGF1 generation.
    Pokrajac A; Frystyk J; Flyvbjerg A; Trainer PJ
    Eur J Endocrinol; 2009 Apr; 160(4):543-8. PubMed ID: 19141605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
    Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
    Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly.
    Ho KK; Jenkins AB; Furler SM; Borkman M; Chisholm DJ
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):271-9. PubMed ID: 1563080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ghrelin drives GH secretion during fasting in man.
    Muller AF; Lamberts SW; Janssen JA; Hofland LJ; Koetsveld PV; Bidlingmaier M; Strasburger CJ; Ghigo E; Van der Lely AJ
    Eur J Endocrinol; 2002 Feb; 146(2):203-7. PubMed ID: 11834429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.
    Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Gettys TW; Taylor IL; Rushakoff RJ; Williams VC; Coker LD
    J Clin Endocrinol Metab; 1990 May; 70(5):1312-8. PubMed ID: 2186058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.